Patrick Soon-Shion, MD, to Deliver Cancer Breakthroughs 2020 Keynote at BIOCOM Global Life Science Partnering Conference

La Jolla, CA – February 24, 2016 – Patrick Soon-Shiong, M.D., founder and CEO of NantWorks, LLCand leader of the Cancer Breakthroughs 2020 program, will deliver the keynote session, “Cancer Breakthroughs 2020 & The National Immunotherapy Coalition,” at the sixth annual Biocom Global Life Science Partnering Conferencean exclusive partnering forum from February 24-25, 2016 at The Lodge at Torrey Pines in La Jolla, California. Biocom will bring together leaders from pharmaceutical and biotech companies to network with from around the globe.

During his keynote, Dr. Soon-Shiong will address the need for exploitation of immunotherapy for the benefit of millions of cancer patients. Session attendees will learn about current breakthroughs in immuno-oncology through the vision of Cancer Breakthroughs 2020. Dr. Soon-Shiong will also touch on the National Immunotherapy Coalition, a historic arrangement that brings together pharmaceutical, biotechnology, national and regional payers and self-insured Fortune 50 companies, academia and oncology centers to accelerate immunotherapies as the next generation standard of care in patients with cancer.

Read More

Cancer Breakthroughs 2020 Reaches First Clinical Trial Milestone: Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients w/Metastatic Colorectal Cancer who Failed All Standard Therapy

Over 30% of patients who failed all standard chemo and antibody therapy remain alive after neo-epitope immunotherapy Ensituximab, with the longest current survivor more than two years after treatment

Results of this promising clinical trial to be presented at the ASCO 2016 Gastrointestinal Cancers Symposium on Saturday, January 23rd by lead author, Richard D. Kim, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

Read More

Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer

Large Pharma, Biotech, Major Payer, Fortune 50 Company, Academia and Community Oncologists Join Forces to Announce Launch of Cancer Breakthroughs 2020 Program

  • Nation’s first insurance coverage of next generation whole genome sequencing and proteomic diagnostic platform in cancer patients
  • Next generation sequencing and precision medicine evolving from research to the clinical trial and cancer care setting
  • Coalition to design, initiate and complete randomized clinical trials at all stages of cancer in up to 20 tumor types in as many as 20,000 patients in multiple phase 1 to 3 trials by year 2020
  • Beneficiaries and patients will undergo next-generation molecular sequencing and gain access to over 60 novel and approved molecules to be tested as immunotherapy combinations in 20,000 cancer patients with cancer across all tumor types: The QUILT Program
Read More

Nation’s First Insurance Coverage of Next-Generation Whole Genome Sequencing and Proteomic Diagnostic Platform Announced by Independence Blue Cross and NantHealth in the War against Cancer

With Today's Announcement Next-Generation Sequencing And Precision Medicine Has Evolved From Research To The Clinical Cancer Setting:

  • CLIA-Certification of a Comprehensive Whole Genome tumor normal DNA, RNA and Quantitative Proteomic Sequencing Test (GPS Cancer™)
  • Insurance coverage for GPS in patients with Cancer
  • Adoption of a payer-provider web-based collaboration platform, called NaviNet Open, enabling doctors and payers to share information in real time with access to over 90% of covered lives in the United States
  • CLIA/CAP certification of a Platinum-Rated Human Tissue Repository
Read More